// App-Quantinova.ai

4511 : A first-in-human study of the oral selective androgen receptor down-regulating drug (SARD) AZD3514 in patients with castration-resistant prostate cancer (CRPC).

Researchers

Presenter

  • Aurelius Gabriel Omlin

Principal Investigators

  • Robert J. Jones

  • Ruud van der Noll

  • Angela Dymond

  • Andrew Dickinson

  • Malcolm Ranson

  • Michael D Malone

  • Johann Sebastian De Bono

  • Tony Elliott

  • Janet Graham

  • Michael Ong

  • Richard D. Finkelman

  • Jan HM Schellens

  • Andrea Zivi

  • Mateus Crespo

  • Glen Clack

  • Joshi J. Alumkal

Medical Centers

  • AstraZeneca, Macclesfield, United Kingdom

  • The Netherlands Cancer Institute, Antoni Van Leeuwenhoek Hospital, Amsterdam, Netherlands

  • AstraZeneca Pharmaceuticals LP, Wilmington, DE

  • The Institute of Cancer Research, The Royal Marsden NHS Foundation Trust, Sutton, United Kingdom

  • AstraZeneca United Kingdom, Macclesfield, United Kingdom

  • AstraZeneca Pharmaceuticals, Cambridge, United Kingdom

  • The Christie NHS Foundation TRUST, Manchester, United Kingdom

  • Beatson West of Scotland Cancer Centre, Glasgow, United Kingdom

  • The Christie NHS Foundation TRUST, Manchester, United Kingdom

  • Oregon Health & Science University, OHSU Knight Cancer Institute, Portland, OR

Locations

  • United States

  • United Kingdom

  • Netherlands

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

  • Urology

Disease

  • Metastatic castration-resistant prostate cancer

Biomarkers

  • Circulating tumor cells

  • Prostate specific antigen

Drug/Treatment

  • Androgen Tear

  • AZD-3514

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • NCT01162395

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved